Abstract
Adenoviral transduction of human bladder cancer cells with human interferon α-2b (Ad-IFN) produces cancer-specific cell death through direct and indirect mechanisms. The indirect mechanisms involve the secreted IFN produced, which kill, IFN protein-sensitive cancer cells, as well as yet unidentified bystander factors, which are cytotoxic to neighboring cancer cells. The direct cell kill results from transfection and expression of Ad-IFN in the cancer cells. As the molecular forms of cytokeratin 18, either caspase cleaved or not, have been associated with apoptotic or necrotic cell death, respectively, we determined if increases in either or both cytokeratin 18 forms could be observed following IFNα protein or Ad-IFN treatment of bladder carcinoma cells. Quantification of M30 and M65 enzyme-linked immunosorbent assays (assays for cytokeratin 18 associated apoptotic and necrotic cell death, respectively) were used as surrogate markers of the cell death produced. In the IFN protein-sensitive RT4 bladder cancer cells, IFN produced primarily M30-related cell death, whereas Ad-IFN treatment resulted in high levels of both M30 and M65. In contrast, conditioned medium from Ad-IFN-treated cells whether from normal human urothelial cells or bladder cancer cells caused increases mainly in M30 levels when added to IFN protein resistant KU7 or UC9 bladder cancer cells, suggesting that the bystander factors present in the conditioned medium produced primarily apoptotic cell death. In addition, a significant increase in M65 levels above that observed for M30 was seen when the IFN protein resistant KU7 and UC9 cells were treated with Ad-IFN, again indicating there is additional necrotic-related cell death produced by Ad-IFN as well. Normal urothelial cells showed no cytotoxicity nor increases in M30 or M65 after Ad-IFN treatment. As intravesical Ad-IFN treatment is presently being evaluated for its efficacy in superficial bladder cancer measurement of M30 and M65 levels in the urine at various time points before and after Ad-IFN treatment may provide not only a biomarker of efficacy but also evidence for the different types and proportion of cell kill produced by the various mechanisms of cell kill in the tumors of individual patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Papageorgiou A, Lashinger L, Millikan R, Benedict WF, Dinney CP, McConkey DJ . Autocrine TRAIL production mediates interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64: 8973–8979.
Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFNα causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFNα protein. Mol Ther 2004; 10: 525–532.
Zhang X-Q, Yang Z, Dong L, Papageorgiou A, McConkey D, Benedict WF . Adenoviral-mediated interferon a overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 2007; 14: 241–250.
Zhang X-Q, Dong L, Chapman E, Benedict WF . Conditioned medium from Ad-IFNα infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: Further evidence for a strong bystander effect. Cancer Gene Ther 2008; 15: 817–822.
Cummings J, Ranson M, Butt F, Moore D, Dive C . Quatification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 2007; 60: 921–924.
Linder S . Cytokeratin markers come of age. Tumor Biol 2007; 28: 189–195.
Kramer G, Erdal H, Mertens MM, Nap M, Mauermann J, Steiner G et al. Differentiation between cell death modes using measurement of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751–1756.
Cummings J, Ranson M, LaCasse E, Ganganagari JR, St-Jean M, Jayson G et al. Method validation and preliminary quantification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Med 2006; 95: 42–48.
Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA . Expression of hTERT immortalizes normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 2006; 25: 5037–5045.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a GU SPORE in Bladder Cancer (P50 CA91846). MF is supported by T32 NIH grant CA079449
Rights and permissions
About this article
Cite this article
Fisher, M., Zhang, XQ., McConkey, D. et al. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon α: possible use as a surrogate marker. Cancer Gene Ther 16, 567–572 (2009). https://doi.org/10.1038/cgt.2009.2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2009.2
Keywords
This article is cited by
-
Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study
Cancer Gene Therapy (2014)
-
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
British Journal of Cancer (2012)
-
Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation
Cancer Gene Therapy (2011)
-
Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity
Cancer Gene Therapy (2011)
-
Autophagy is induced by adenoviral-mediated interferon α treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced
Cancer Gene Therapy (2010)